Purpose
To report the functional and structural outcomes, and safety of intravitreal Aflibercept (Eylea) injection in patients with wet age-related macular degeneration (AMD).
Methods
This was a retrospective, non-comparative, interventional case series. All the patients who received intravitreal Aflibercept injection for wet AMD between July 2013 and July 2014 (1-year period) were included in this study. Patients’ clinical notes were reviewed for relevant data, including demographic factors, best-corrected visual acuity (BCVA) and central macular thickness (CMT) on optical coherence topography (OCT) at baseline, post-loading dose (3 sequential monthly injections), 6th month and 12th month, fundus fluorescein angiogram findings, pre-treatment ocular co-morbidities and complications during the treatment period.
Results
During the study period, a total of 350 patients were identified. The mean age was 79.9 ± 8.4 years with a male:female ratio of 0.85. The mean follow-up period 8.7 ± 3.9 months. The mean baseline BCVA was 52.6 ±16.5 letters. There was a mean gain of 0.2 letters at post-loading phase (p=0.980), 6.4 letters at 6th month (p=0.487), and 6.3 letters at 12th month (p=0.595). The mean baseline CMT was 329 ± 97 µm and improved to 244 ± 90 µm at post-loading phase (p=0.002), 225 ± 51 µm at 6th month (p<0.001), and 223 ± 71 µm at 12th month (p=0.031). No complication was noted during the study period except for a case of retinal pigment epithelial (RPE) rip.
Conclusions
Our study demonstrates the efficacy and safety of intravitreal Aflibercept injection in patients with wet AMD in a real-world setting. Our data parallels the outcome reported in VIEW 1 and VIEW 2 studies.